The ARHGAP17 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population, derived from the A-549 human lung adenocarcinoma cell line, in which the ARHGAP17 gene has been disrupted. This product provides a loss-of-function model for investigating Rho GTPase signaling pathways in epithelial cancer research.
The host A-549 cell line, established from a male patient with lung adenocarcinoma, serves as a well-characterized model for alveolar type II epithelium and lung adenocarcinoma. These adherent epithelial cells are widely utilized in cancer research to study processes such as proliferation, migration, and invasion, making them an appropriate context for examining the role of genes involved in cytoskeletal dynamics.
ARHGAP17 encodes a Rho GTPase-activating protein (GAP) that accelerates GTP hydrolysis on the Rho family GTPases RAC1 and CDC42, thereby negatively regulating their activity. In the absence of ARHGAP17, RAC1/CDC42 signaling is elevated, leading to enhanced downstream activation of effectors such as PAK, WAVE, and the actin-nucleating Arp2/3 complex, which promote actin polymerization and cell migration. Upstream regulators include epidermal growth factor (EGF) receptor signaling and integrin-mediated adhesion, which modulate ARHGAP17 function. This gene thus acts as a key node linking extracellular cues to cytoskeletal reorganization.
In the A-549 cellular context, disruption of ARHGAP17 is anticipated to potentiate RAC1/CDC42-driven pathways, potentially altering cell adhesion, migration, and invasive properties relevant to adenocarcinoma progression. This polyclonal knockout population serves as a valuable experimental system for dissecting the contribution of Rho GTPase regulation to lung cancer cell behavior and for evaluating pharmacological interventions targeting these signaling networks.
Researchers can employ this knockout model in diverse functional assays, including Transwell migration/invasion, wound healing, and cell adhesion studies. Rho GTPase activity pull-down assays and immunofluorescence staining for F-actin enable direct assessment of cytoskeletal dynamics, while Western blotting for phospho-PAK provides a readout of downstream signaling. Applications extend from basic exploration of Rho GTPase signaling in lung cancer to drug target validation and functional screening of GAPs. For further information, please contact Ascent Research.
